版本:
中国

BRIEF-FDA approves treatment for metastatic merkel cell carcinoma

March 23 U.S. FDA:

* Granted accelerated approval to Bavencio for treatment of adults, pediatric patients 12 years and older with metastatic merkel cell carcinoma

* Further clinical trials are required to confirm Bavencio’s clinical benefit Source text - (bit.ly/2nN2hTA) Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐